UAMS.EDU

Ruud P.M. Dings, Ph.D., M.Sc.

Dr. Dings received his M.Sc., in Biological Health Sciences from the University of Maastricht, Maastricht, The Netherlands in 2000. He obtained his Ph.D. in 2003 in Internal Medicine, Experimental Oncology from the University of Maastricht, The Netherlands and was a Postdoctoral Associate in Biochemistry, Molecular Biology and Biophysics at the University of Minnesota Medical School, Minneapolis, MN, USA.

https://sites.google.com/site/dingslaboratory/home

rpmdings@uams.edu

501.526.7876

Publications:

38.       Dings RPM, Levine JI, MacDonald J, Raymond E, HoyeTR, Mayo H. Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer. Invest New Drugs. 2013:31(5):1142-50. 

37.       Dings RPM, Kumar N, MillerMC, LorenM, RangwalaH, HoyeT, MayoKH. Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1. J Pharmacol Exp Ther. 2013;344(3):589-99. 

36.       Dings RPM, Haseman JR1, Leslie DB, Luong M, Dunn DL, and Mayo KH. Bacterial membrane disrupting dodecapeptide SC4 improves survival of mice challenged with Pseudomonas aeruginosa. Biochim Biophys Acta. 2013;1830(6):3454-7.

35.       Dings RPM, Miller MC#, Raymond E, Nesmelova I, Astorgues-Xerri L, Kumar N, Serova M, Mayo KH. Anti-tumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding. J Med Chem. 2012;55(11):5121-9.    #RPM Dings and MC Miller contributed equally to this work. 

34.       SongCW, LeeH, Dings RPM, WilliamsB, PowersJ, Dos SantosT, ChoiBH, Park HJ.Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Scientific Reports. 2012;2:362-71. 

33.       Griffin RJ, Koonce N, Dings RPM, Moros E,  Brauer-Kirsche E, Corry P. Microbeam radiation therapy alters vascular architecture and tumor oxygenation and is enhanced by a galectin-1 targeted anti-angiogenic peptide. Radiation Research. 2012;177(6):804-12.

32.       Apana SM, Griffin RJ, Koonce NA, Webber JS, Dings RPM, Mayo KH, Berridge MS. Synthesis of [18F]anginex with high specific activity [18F]fluorobenzaldehyde for targeting angiogenic activity in solid tumors. J Label Compd Radiopharm. 2011;54(11):708-713.

31.       Dings RPM, Vang KB, Castermans K, Popescu F, Zhang Y, Oude Egbrink MG, Mescher M, Farrar M, Griffioen AW, Mayo KH. Enhancement of T-cell mediated anti-tumor response: angiostatic adjuvant to immunotherapy against cancer. Clin Cancer Res. 2011;17(10):3134-45.

30.       Dings RPM, Loren ML, Mikkelson S, Mayo KH, Corry P, Griffin RJ. Tumor thermo-tolerance, a physiological phenomenon involving vessel normalization. Int J Hyperthermia. 2011;27(1):42-52.

29.       Dings RPM, Van Laar ES, Webber J, Zhang Y, Waters SJ, MacDonald JR Mayo KH. Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulvene. Bioconjug Chem. 2010; 21(1):20-7.

28.       Griffin R, Dings RPM, Jamshidi-Parsian A, Song C. Mild temperature hyperthermia and radiation therapy: role of tumor vascular thermotolerance and relevant physiological factors. Int J Hyperthermia. 2010; 26(3):256-63.

27.       Dings RPM, Haseman JR, Mayo KH. Probing structure-activity relationships in bactericidal peptide ßpep-25. Biochem J. 2008; 414(1):143-50. 

26.       Dings RPM, Van Laar ES, Webber J, Griffin RJ, Zhang Y, Waters SJ, MacDonald JR, Mayo KH. Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer Lett. 2008; 265(2):270-80. 

25.       Saarinen NM, Wärri A, Dings RPM, Airio M, Smeds AI, Mäkelä S. Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats. Int J Cancer. 2008; 123(5):1196-204T. 

24.       Dings RPM, Mayo KH. A Journey in structure-based drug discovery: from designed peptides to protein-surface topomimetics as antibiotic and antiangiogenic agents.    Acc Chem Res. 2007; 40(10):1057-65. 

23.       Dings RPM, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ. Scheduling of radiation with angiogenesis inhibitors Anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res. 2007; 13 3395-3402. 

22.       Schumacher JJ, Dings RPM, Cosin J, Subramanian IV, Auersperg N, Ramakrishnan S. Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells.    Cancer Res. 2007; 67(8):3683-90. 

21.       Amano M, Suzuki M, Andoh S, Monzen H, Terai K, Song CW, Mayo KH, Hasegawa T, Dings RPM, Griffin RJ. Anti-angiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay.  Jpn J Clin Oncol. 2007; 12(1):42-7. 

20.       Chen X#, Dings RPM#, Nesmelova I, Debbert S, Haseman JR, Maxwell J, Hoye TR, Mayo KH. Topomimetics of amphipathic ß-sheet and helix-forming bactericidal peptides neutralize liposaccharide endotoxins. J Med Chem. 2006; 49(26):7754-65.    #X Chen and RPM Dings contributed equally to this work.

19.       Thijssen VLJL, Postel R, Brandwijk RJMGE, Dings RPM, Nesmelova I, Satijn S, Verhofstad N, Nakabeppu Y, Baum LG, Bakkers J, Mayo KH, Poirier F, Griffioen AW. Galectin-1 is essential in tumor angiogenesis and is a target for anti-angiogenesis therapy. Proc Natl Acad Sci USA. 2006; 103(43):15975-80. 

18.       Hellebrekers DM, Castermans K, Vire E, Dings RPM, Hoebers NT, Mayo KH, Oude Egbrink MG, Molema G, Fuks F, van Engeland M, and Griffioen AW. Epigenetic regulation of tumor endothelial cell anergy; silencing of ICAM-1 by histone modifications.     Cancer Res. 2006; 66(22):10770-7. 

17.       Dings RPM#, Chen X#, Nesmelova I, Haseman J, Hellebrekers DMEI, Van Eijk LI, Zhang Y, Hoye TR, Griffioen AW, Mayo KH. Design of non-peptidic helix/sheet topomimetics: applications to inhibition of angiogenesis and tumor growth in mice. J Natl Cancer Inst. 2006; 98(13):932-6. #X Chen and RPM Dings contributed equally to this work. 

16.       Van Beijnum J, Dings RPM, Zwaans B, Van der Linden E, Raemakers FCS, Mayo KH, Griffioen AW. Gene expression of tumor angiogenesis dissected; specific targeting of colon cancer angiogenic vasculature. Blood. 2006; 108(7):2339-48. 

15.       Brandwijk RJMGE, Dings RPM, van der Linden E, Mayo KH, Thijssen VLJL, Griffioen AW. Anti-angiogenesis and anti-tumor activity of recombinant anginex: a promise for gene therapy approaches. Biochem Biophys Res Commun. 2006; 349(3):1073-8.T 

14.       Griffin RJ, Molema G, Dings RPM. Angiogenesis treatment, new concepts on the horizon. Angiogenesis. 2006; 9(2):67-72.

 13.       Dirkx AEM, oude Egbrink MGA, Castermans K, Thijssen VLJL, Dings RPM,van der Schaft DWJ, Kwee L, Mayo KH, Wagstaff J, Bouma-ter Steege JCA, Griffioen AW. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 2006; 20(6):621-30. 

12.       Dings RPM, Williams BW, Song SW, Griffioen AW, Mayo KH, Griffin RJ. The designed angiostatic peptide anginex causes endothelial cell death and alters physiology and radiation response in multiple carcinoma models. Int J Cancer. 2005; 115(2):312-9. 

11.       Brandwijk RJ, Nesmelova I, Dings RPM, Mayo KH, Thijssen VL, Griffioen AW. Cloning an artificial gene encoding angiostatic anginex: From designed peptide to functional recombinant protein. Biochem Biophys Res Commun. 2005; 333(4):1261-8. 

10.       Thijssen VLJL, Brandwijk RJMGE, Dings RPM, Griffioen AW. Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Exp Cell Res. 2004; 299(2):286-93. 

9.         Wild R, Dings RPM, Ramakrishnan S. Carboplatin selectively induces the VEGF stress response in endothelial cells: synergistic inhibition of tumor growth by combination treatment with antibody to VEGF. Int J Cancer. 2004; 10(3):343-51.

8.         Wild R, Yokoyama Y, Dings RPM, Ramakrishnan S. VEGF-Toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis. Breast Cancer Res Treat. 2004; 85(2):161-71. 

7.         Dings RPM, Nesmelova I, Griffioen AW, Mayo KH. Discovery and development of anti-angiogenic peptides: a structural link. Angiogenesis. 2003; 6(2):83-91. 

6.         Mayo KH, Dings RPM, Flader C, Nesmelova I, Hargittai B, Van der Schaft DW, Van Eijk LI, Walek D, Haseman J, Hoye TR, Griffioen AW. Design of a partial-peptide mimetic of anginex with anti-angiogenic and anti-cancer activity. J Biol Chem. 2003; 46:45746-52. 

5.         Dings RPM, Arroyo MM, Lockwood NA, Van Eijk LI, Haseman JR, Griffioen AW, Mayo KH. Beta-sheet is the bioactive conformation of the anti-angiogenic anginex peptide.Biochem J. 2003; 23:281-88. 

4.         Dings RPM, van der Schaft, Hargittai B, Haseman J, Griffioen AW, Mayo KH. Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Lett. 2003;194:55-56. 

3.         Dings RPM, Yokoyama Y, Ramakrishnan S, Griffioen AW, Mayo KH. The designed angiostatic peptide anginex synergistically improves chemotherapy and anti-angiogenesis therapy with angiostatin. Cancer Res. 2003; 63:382-5. 

2.         van der Schaft DW, Dings RPM, de Lussanet QG, van Eijk LI, Nap AW, Beets-Tan RG, Bouma-Ter Steege JC, Wagstaff J, Mayo KH, Griffioen AW. The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J. 2002; 16:1991-93. 

1.         Tromp SC, oude Egbrink MG, Dings RPM, van Velzen S, Slaaf DW, Hillen HF, Tangelder GJ, Reneman RS, Griffioen AW. Tumor angiogenesis factors reduce leukocyte adhesion in vivo. Int Immunol. 2000; 12:671-6.

Book Chapters

Dings RPM, Klein M, Mayo KH. Nonpeptidic mimetics as cancer sensitizing agents.Book series: Cancer Drug Discovery & Development (series Editor Beverly A. Teicher)Contribution to the book series “ Sensitization of Cancer Cells by Chemo/Immuno/Radio-therapy” edited by Dr. Benjamin Bonavida, 2008, Humana press, pp.306-325. 

Nesmelova IV, Dings RPM, Mayo KH. Understanding Galectin Structure-Function Relationships to Design Effective Antagonists. Contribution to the book “Galectins” edited by Anatole Klyosov, 2008, Wiley; Oxford University Press, pp 33-70.

Patents:

US20070010438 – Tumor treatment using beta-sheet peptides and radiotherapy.

US2011058796 – Cytotoxic agents against cancer cells and uses thereof.